Acute Shift in Glutamate Concentrations Following Experimentally Induced Panic with Cholecystokinin Tetrapeptide—A 3T-MRS Study in Healthy Subjects
According to preclinical studies, glutamate has been implicated in the pathogenesis of anxiety. In order to elucidate the role of glutamate in anxiety and panic in humans, brain glutamate+glutamine (Glx) levels were measured during cholecystokinin-tetrapeptide (CCK-4)-induced panic using magnetic re...
Saved in:
Published in | Neuropsychopharmacology (New York, N.Y.) Vol. 38; no. 9; pp. 1648 - 1654 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basingstoke
Nature Publishing Group
01.08.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | According to preclinical studies, glutamate has been implicated in the pathogenesis of anxiety. In order to elucidate the role of glutamate in anxiety and panic in humans, brain glutamate+glutamine (Glx) levels were measured during cholecystokinin-tetrapeptide (CCK-4)-induced panic using magnetic resonance spectroscopy (MRS). Eighteen healthy subjects underwent a CCK-4 challenge. MR spectra were obtained from the anterior cingulate cortex (ACC) using a single voxel point-resolved spectroscopy method and analyzed using LCModel. A combined fitting of Glx was performed. Panic was assessed using the Acute Panic Inventory (API) and Panic Symptom Scale (PSS) scores. Moreover, hypothalamic-pituitary-adrenal axis stimulation was monitored throughout the challenge. There was a significant panic response following CCK-4 as revealed by a marked increase in both the panic scores (API: F(1,17)=149.41; p<0.0001; PSS: F(1,17)=88.03; p<0.0001) and heart rate (HR: F(1,17)=72.79; p<0.0001). MRS measures showed a significant increase of brain Glx/creatine (Glx/Cr) levels peaking at 2-10 min after challenge (F(1,17)=15.94; p=0.001). There was also a significant increase in CCK-4-related cortisol release (F(6,11)=8.68; p=0.002). Finally, significant positive correlations were found between baseline Glx/Cr and both APImax (r=0.598; p=0.009) and maximum heart rate (HR(max)) during challenge (r=0.519; p=0.027). Our results suggest that CCK-4-induced panic is accompanied by a significant glutamate increase in the bilateral ACC. The results add to the hypothesis of a disturbance of the inhibitory-excitatory equilibrium and suggest that apart from static alterations rapid and dynamic neurochemical changes might also be relevant for the neural control of panic attacks. |
---|---|
AbstractList | According to preclinical studies, glutamate has been implicated in the pathogenesis of anxiety. In order to elucidate the role of glutamate in anxiety and panic in humans, brain glutamate+glutamine (Glx) levels were measured during cholecystokinin-tetrapeptide (CCK-4)-induced panic using magnetic resonance spectroscopy (MRS). Eighteen healthy subjects underwent a CCK-4 challenge. MR spectra were obtained from the anterior cingulate cortex (ACC) using a single voxel point-resolved spectroscopy method and analyzed using LCModel. A combined fitting of Glx was performed. Panic was assessed using the Acute Panic Inventory (API) and Panic Symptom Scale (PSS) scores. Moreover, hypothalamic-pituitary-adrenal axis stimulation was monitored throughout the challenge. There was a significant panic response following CCK-4 as revealed by a marked increase in both the panic scores (API: F(1,17)=149.41; p<0.0001; PSS: F(1,17)=88.03; p<0.0001) and heart rate (HR: F(1,17)=72.79; p<0.0001). MRS measures showed a significant increase of brain Glx/creatine (Glx/Cr) levels peaking at 2-10 min after challenge (F(1,17)=15.94; p=0.001). There was also a significant increase in CCK-4-related cortisol release (F(6,11)=8.68; p=0.002). Finally, significant positive correlations were found between baseline Glx/Cr and both APImax (r=0.598; p=0.009) and maximum heart rate (HR(max)) during challenge (r=0.519; p=0.027). Our results suggest that CCK-4-induced panic is accompanied by a significant glutamate increase in the bilateral ACC. The results add to the hypothesis of a disturbance of the inhibitory-excitatory equilibrium and suggest that apart from static alterations rapid and dynamic neurochemical changes might also be relevant for the neural control of panic attacks. According to preclinical studies, glutamate has been implicated in the pathogenesis of anxiety. In order to elucidate the role of glutamate in anxiety and panic in humans, brain glutamate+glutamine (Glx) levels were measured during cholecystokinin-tetrapeptide (CCK-4)-induced panic using magnetic resonance spectroscopy (MRS). Eighteen healthy subjects underwent a CCK-4 challenge. MR spectra were obtained from the anterior cingulate cortex (ACC) using a single voxel point-resolved spectroscopy method and analyzed using LCModel. A combined fitting of Glx was performed. Panic was assessed using the Acute Panic Inventory (API) and Panic Symptom Scale (PSS) scores. Moreover, hypothalamic-pituitary-adrenal axis stimulation was monitored throughout the challenge. There was a significant panic response following CCK-4 as revealed by a marked increase in both the panic scores (API: F(1,17)=149.41; p<0.0001; PSS: F(1,17)=88.03; p<0.0001) and heart rate (HR: F(1,17)=72.79; p<0.0001). MRS measures showed a significant increase of brain Glx/creatine (Glx/Cr) levels peaking at 2-10 min after challenge (F(1,17)=15.94; p=0.001). There was also a significant increase in CCK-4-related cortisol release (F(6,11)=8.68; p=0.002). Finally, significant positive correlations were found between baseline Glx/Cr and both API sub(max) (r=0.598; p=0.009) and maximum heart rate (HR sub(max)) during challenge (r=0.519; p=0.027). Our results suggest that CCK-4-induced panic is accompanied by a significant glutamate increase in the bilateral ACC. The results add to the hypothesis of a disturbance of the inhibitory-excitatory equilibrium and suggest that apart from static alterations rapid and dynamic neurochemical changes might also be relevant for the neural control of panic attacks. According to preclinical studies, glutamate has been implicated in the pathogenesis of anxiety. In order to elucidate the role of glutamate in anxiety and panic in humans, brain glutamate+glutamine (Glx) levels were measured during cholecystokinin-tetrapeptide (CCK-4)-induced panic using magnetic resonance spectroscopy (MRS). Eighteen healthy subjects underwent a CCK-4 challenge. MR spectra were obtained from the anterior cingulate cortex (ACC) using a single voxel point-resolved spectroscopy method and analyzed using LCModel. A combined fitting of Glx was performed. Panic was assessed using the Acute Panic Inventory (API) and Panic Symptom Scale (PSS) scores. Moreover, hypothalamic-pituitary-adrenal axis stimulation was monitored throughout the challenge. There was a significant panic response following CCK-4 as revealed by a marked increase in both the panic scores (API: F(1,17)=149.41; p<0.0001; PSS: F(1,17)=88.03; p<0.0001) and heart rate (HR: F(1,17)=72.79; p<0.0001). MRS measures showed a significant increase of brain Glx/creatine (Glx/Cr) levels peaking at 2-10 min after challenge (F(1,17)=15.94; p=0.001). There was also a significant increase in CCK-4-related cortisol release (F(6,11)=8.68; p=0.002). Finally, significant positive correlations were found between baseline Glx/Cr and both APImax (r=0.598; p=0.009) and maximum heart rate (HR(max)) during challenge (r=0.519; p=0.027). Our results suggest that CCK-4-induced panic is accompanied by a significant glutamate increase in the bilateral ACC. The results add to the hypothesis of a disturbance of the inhibitory-excitatory equilibrium and suggest that apart from static alterations rapid and dynamic neurochemical changes might also be relevant for the neural control of panic attacks.According to preclinical studies, glutamate has been implicated in the pathogenesis of anxiety. In order to elucidate the role of glutamate in anxiety and panic in humans, brain glutamate+glutamine (Glx) levels were measured during cholecystokinin-tetrapeptide (CCK-4)-induced panic using magnetic resonance spectroscopy (MRS). Eighteen healthy subjects underwent a CCK-4 challenge. MR spectra were obtained from the anterior cingulate cortex (ACC) using a single voxel point-resolved spectroscopy method and analyzed using LCModel. A combined fitting of Glx was performed. Panic was assessed using the Acute Panic Inventory (API) and Panic Symptom Scale (PSS) scores. Moreover, hypothalamic-pituitary-adrenal axis stimulation was monitored throughout the challenge. There was a significant panic response following CCK-4 as revealed by a marked increase in both the panic scores (API: F(1,17)=149.41; p<0.0001; PSS: F(1,17)=88.03; p<0.0001) and heart rate (HR: F(1,17)=72.79; p<0.0001). MRS measures showed a significant increase of brain Glx/creatine (Glx/Cr) levels peaking at 2-10 min after challenge (F(1,17)=15.94; p=0.001). There was also a significant increase in CCK-4-related cortisol release (F(6,11)=8.68; p=0.002). Finally, significant positive correlations were found between baseline Glx/Cr and both APImax (r=0.598; p=0.009) and maximum heart rate (HR(max)) during challenge (r=0.519; p=0.027). Our results suggest that CCK-4-induced panic is accompanied by a significant glutamate increase in the bilateral ACC. The results add to the hypothesis of a disturbance of the inhibitory-excitatory equilibrium and suggest that apart from static alterations rapid and dynamic neurochemical changes might also be relevant for the neural control of panic attacks. According to preclinical studies, glutamate has been implicated in the pathogenesis of anxiety. In order to elucidate the role of glutamate in anxiety and panic in humans, brain glutamate+glutamine (Glx) levels were measured during cholecystokinin-tetrapeptide (CCK-4)-induced panic using magnetic resonance spectroscopy (MRS). Eighteen healthy subjects underwent a CCK-4 challenge. MR spectra were obtained from the anterior cingulate cortex (ACC) using a single voxel point-resolved spectroscopy method and analyzed using LCModel. A combined fitting of Glx was performed. Panic was assessed using the Acute Panic Inventory (API) and Panic Symptom Scale (PSS) scores. Moreover, hypothalamic–pituitary–adrenal axis stimulation was monitored throughout the challenge. There was a significant panic response following CCK-4 as revealed by a marked increase in both the panic scores (API: F(1,17)=149.41; p <0.0001; PSS: F(1,17)=88.03; p <0.0001) and heart rate (HR: F(1,17)=72.79; p <0.0001). MRS measures showed a significant increase of brain Glx/creatine (Glx/Cr) levels peaking at 2–10 min after challenge (F(1,17)=15.94; p =0.001). There was also a significant increase in CCK-4-related cortisol release (F(6,11)=8.68; p =0.002). Finally, significant positive correlations were found between baseline Glx/Cr and both API max ( r =0.598; p =0.009) and maximum heart rate (HR max ) during challenge ( r =0.519; p =0.027). Our results suggest that CCK-4-induced panic is accompanied by a significant glutamate increase in the bilateral ACC. The results add to the hypothesis of a disturbance of the inhibitory–excitatory equilibrium and suggest that apart from static alterations rapid and dynamic neurochemical changes might also be relevant for the neural control of panic attacks. |
Author | Ohrmann, Patricia Domschke, Katharina Gencheva, Elena Zavorotnyy, Maxim Pfleiderer, Bettina Ruland, Tillmann Kugel, Harald Diemer, Julia Heindel, Walter Arolt, Volker Zwanzger, Peter |
Author_xml | – sequence: 1 givenname: Peter surname: Zwanzger fullname: Zwanzger, Peter – sequence: 2 givenname: Maxim surname: Zavorotnyy fullname: Zavorotnyy, Maxim – sequence: 3 givenname: Elena surname: Gencheva fullname: Gencheva, Elena – sequence: 4 givenname: Julia surname: Diemer fullname: Diemer, Julia – sequence: 5 givenname: Harald surname: Kugel fullname: Kugel, Harald – sequence: 6 givenname: Walter surname: Heindel fullname: Heindel, Walter – sequence: 7 givenname: Tillmann surname: Ruland fullname: Ruland, Tillmann – sequence: 8 givenname: Patricia surname: Ohrmann fullname: Ohrmann, Patricia – sequence: 9 givenname: Volker surname: Arolt fullname: Arolt, Volker – sequence: 10 givenname: Katharina surname: Domschke fullname: Domschke, Katharina – sequence: 11 givenname: Bettina surname: Pfleiderer fullname: Pfleiderer, Bettina |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27618930$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23463151$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkk2L1DAcxoOsuLOjJ-8SEEGQjknTpu1lYRj2DVYUZ4S9hTRNtxkzSW1Sd3vbD6Ff0E9iOjOuunjwFMjzy5P_y3MEDow1EoDnGM0wIvlb07azGGEyo_gRmOAsQRElydUBmKC8IBEm5OoQHDm3RginGc2fgMOYJJTgFE_A97novYTLRtUeKgPPdO_5hoerhTVCGt9xr6xx8NRqbW-UuYYnt63s1CZoXOsBXpiqF7KCH7hRAt4o38BFY7UUg_P2szLBdCWDTStbryr54-7bHJJV9O7jEi59Xw3jr-eSa98McNmXaym8ewoe11w7-Wx_TsGn05PV4jy6fH92sZhfRiJFqY8ylNEyIWVaZlWNqxLVEktEiwqVuCw4ihNMiirmQUiygqZVTkpSiiCSWOYiJVNwvPNt-3Ijq12_mrWhPd4NzHLF_laMati1_cpIhrM0uE_B671BZ7_00nm2UU5IrbmRtncMJ7gglKbF_6AI0TjJExTQlw_Qte07EyaxpXBYKxoNX_xZ_H3Vv5YbgFd7gDvBdd1xI5T7zWV06xS4NztOdNa5Ttb3CEZsjBgLEWNjxBgdXfEDWii_DUmYkNL_fPMTZazXQA |
CODEN | NEROEW |
CitedBy_id | crossref_primary_10_1017_neu_2021_41 crossref_primary_10_1038_s41398_024_02966_0 crossref_primary_10_3389_fpsyt_2021_813518 crossref_primary_10_1186_s12920_020_0699_9 crossref_primary_10_1016_j_neubiorev_2019_02_004 crossref_primary_10_3390_ijms23179628 crossref_primary_10_1002_biof_2081 crossref_primary_10_1038_npp_2014_104 crossref_primary_10_3390_cells13141228 crossref_primary_10_1192_j_eurpsy_2020_62 crossref_primary_10_1001_jamanetworkopen_2020_13211 crossref_primary_10_1177_0269881114563634 crossref_primary_10_1016_j_pscychresns_2014_03_001 crossref_primary_10_5498_wjp_v7_i1_12 crossref_primary_10_1016_j_neubiorev_2014_07_016 crossref_primary_10_1124_pr_114_009126 crossref_primary_10_1016_j_euroneuro_2015_07_011 crossref_primary_10_1016_j_jpsychires_2013_11_013 crossref_primary_10_1038_s41386_018_0027_7 crossref_primary_10_1016_j_bbadis_2020_165884 crossref_primary_10_1016_j_nicl_2017_01_001 crossref_primary_10_1016_j_pbb_2014_04_004 crossref_primary_10_1002_brb3_1616 crossref_primary_10_1038_npp_2014_93 crossref_primary_10_5702_massspectrometry_S0049 crossref_primary_10_1371_journal_pone_0136739 crossref_primary_10_1016_j_cortex_2019_02_021 crossref_primary_10_1124_pharmrev_120_000043 crossref_primary_10_1007_s11682_020_00259_w |
Cites_doi | 10.2174/138161208786848784 10.1016/S0006-3223(99)00159-6 10.1016/j.pbb.2011.04.010 10.1016/S0006-3223(99)00118-3 10.1016/0301-0082(95)00047-X 10.1016/S0006-3223(99)00230-9 10.1006/nimg.2002.1308 10.1007/978-3-642-68962-8 10.1001/archpsyc.55.8.715 10.1016/S0925-4927(03)00003-9 10.1016/j.neuroimage.2006.01.035 10.1038/nrd3295 10.1002/(SICI)1520-6394(1998)8:1<1::AID-DA1>3.0.CO;2-G 10.1176/appi.ajp.159.1.145 10.1016/j.neuroimage.2006.10.004 10.1016/0165-1781(87)90002-3 10.1002/mrm.1910300604 10.1097/00001756-200502080-00024 10.1016/S0924-9338(97)83297-X 10.1176/ajp.151.2.261 10.1007/s00406-012-0352-5 10.1038/sj.npp.1300572 10.1038/37601 10.1001/archpsyc.60.2.161 10.1016/j.pscychresns.2009.02.005 10.1016/j.pnpbp.2011.05.006 10.1038/361031a0 10.2165/00023210-200822090-00004 10.1001/archpsyc.58.6.556 10.1001/archgenpsychiatry.2010.93 10.1016/j.pbb.2011.01.009 10.1001/archpsyc.65.10.1166 10.1016/j.cll.2010.07.006 10.1016/j.biopsych.2012.09.004 10.1126/science.1175055 10.1016/j.biopsych.2009.07.036 10.1016/S0091-3057(01)00698-0 10.1176/appi.ajp.2010.09070994 10.1002/1096-9861(20000703)422:3<352::AID-CNE3>3.0.CO;2-F 10.1192/bjp.176.3.229 10.2165/11533230-000000000-00000 10.1002/hbm.20522 10.1176/appi.ajp.157.4.493 10.1007/BF00589901 10.1001/archpsyc.55.9.801 10.1001/archpsyc.61.11.1136 10.1002/da.21919 10.1038/sj.npp.1300131 10.1001/archpsyc.56.11.1043 10.1016/S0924-977X(03)00100-7 10.1176/appi.ajp.162.12.2379 10.1001/archpsyc.1988.01800290027004 10.1016/j.neubiorev.2009.05.009 10.1038/sj.mp.4000778 10.1016/j.neuroimage.2011.05.048 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS Copyright Nature Publishing Group Aug 2013 Copyright © 2013 American College of Neuropsychopharmacology 2013 American College of Neuropsychopharmacology |
Copyright_xml | – notice: 2015 INIST-CNRS – notice: Copyright Nature Publishing Group Aug 2013 – notice: Copyright © 2013 American College of Neuropsychopharmacology 2013 American College of Neuropsychopharmacology |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7TK 7X7 7XB 88E 88G 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2M M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
DOI | 10.1038/npp.2013.61 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Psychology Database Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest One Psychology Neurosciences Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Glutamate increase during induced panic attacks |
EISSN | 1740-634X |
EndPage | 1654 |
ExternalDocumentID | PMC3717541 3020276571 23463151 27618930 10_1038_npp_2013_61 |
Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Germany |
GeographicLocations_xml | – name: Germany |
GroupedDBID | --- -DZ -Q- 0R~ 29N 2WC 36B 39C 4.4 406 5RE 70F 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AANZL AASML AAYXX AAYZH ABAKF ABBRH ABDBE ABFSG ABIVO ABJNI ABLJU ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMFV ACMJI ACPRK ACRQY ACSTC ACZOJ ADBBV ADFRT AEFQL AEJRE AEMSY AENEX AESKC AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AHWEU AIGIU AIXLP AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ASPBG ATHPR AVWKF AYFIA AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CITATION CS3 DIK DNIVK DPUIP DWQXO E3Z EBLON EBS EE. EIOEI EJD EMB EMOBN F5P FDB FDQFY FERAY FIZPM FSGXE FYUFA GNUQQ GX1 HCIFZ HMCUK HYE HZ~ IWAJR JSO JZLTJ KQ8 M1P M2M M7P MK0 NQJWS O9- OK1 P2P P6G PHGZM PHGZT PQQKQ PROAC PSQYO PSYQQ Q2X RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TR2 UKHRP W2D ZGI --K 1B1 53G 5VS AACDK AAEDT AALRI AAQFI AAQXK AATNV AAXUO ABMAC ABWVN ACIUM ACRPL ADMUD ADNMO AILAN CAG COF FEDTE FGOYB FIGPU HVGLF IHE IQODW LGEZI LOTEE M41 NADUK NQ- NXXTH R2- RIG RNS RPZ SEW SSZ ZKB ABRTQ ACVFH ADCNI AEUPX AFPUW AGQPQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 3V. 7TK 7XB 8FE 8FH 8FK K9. LK8 PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c505t-7076b43b5b7df1db0fe1e069d0b1b9a024139d2ab0f47965d83b3bcb1b32e8c53 |
IEDL.DBID | 7X7 |
ISSN | 0893-133X 1740-634X |
IngestDate | Thu Aug 21 13:47:29 EDT 2025 Tue Aug 05 11:34:38 EDT 2025 Fri Jul 11 04:47:44 EDT 2025 Sat Aug 23 14:24:21 EDT 2025 Mon Jul 21 05:49:40 EDT 2025 Wed Apr 02 07:26:02 EDT 2025 Tue Jul 01 01:05:24 EDT 2025 Thu Apr 24 23:06:33 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | Human panic attacks Panic Healthy subject Induction Central nervous system Anxiety disorder magnetic resonance spectroscopy Experimental study Glutamate Neuropeptide Encephalon Cingulate cortex Panic attack Excitatory aminoacid Neurotransmitter Anxiety Cholecystokinin CCK-4 anterior cingulate cortex |
Language | English |
License | http://www.springer.com/tdm CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c505t-7076b43b5b7df1db0fe1e069d0b1b9a024139d2ab0f47965d83b3bcb1b32e8c53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 These authors contributed equally to this work. |
OpenAccessLink | https://www.nature.com/articles/npp201361.pdf |
PMID | 23463151 |
PQID | 1400189301 |
PQPubID | 33935 |
PageCount | 7 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3717541 proquest_miscellaneous_1419366591 proquest_miscellaneous_1400624840 proquest_journals_1400189301 pubmed_primary_23463151 pascalfrancis_primary_27618930 crossref_primary_10_1038_npp_2013_61 crossref_citationtrail_10_1038_npp_2013_61 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-08-01 |
PublicationDateYYYYMMDD | 2013-08-01 |
PublicationDate_xml | – month: 08 year: 2013 text: 2013-08-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Basingstoke |
PublicationPlace_xml | – name: Basingstoke – name: England – name: New York |
PublicationTitle | Neuropsychopharmacology (New York, N.Y.) |
PublicationTitleAlternate | Neuropsychopharmacology |
PublicationYear | 2013 |
Publisher | Nature Publishing Group |
Publisher_xml | – name: Nature Publishing Group |
References | JC Ballenger (BFnpp201361_CR3) 1988; 45 MW Otto (BFnpp201361_CR35) 2010; 67 J Bradwejn (BFnpp201361_CR8) 1994; 151 R Rupprecht (BFnpp201361_CR45) 2010; 9 J Gallinat (BFnpp201361_CR15) 2007; 34 G Leicht (BFnpp201361_CR28) 2013; 73 C Nothdurfter (BFnpp201361_CR34) 2012; 262 G Hasler (BFnpp201361_CR19) 2008; 65 OD Creutzfeldt (BFnpp201361_CR10) 1983 JM Gorman (BFnpp201361_CR17) 2000; 157 D Eser (BFnpp201361_CR14) 2009; 30 P Zwanzger (BFnpp201361_CR58) 2003; 28 M Kellner (BFnpp201361_CR24) 2000; 47 RJ Maddock (BFnpp201361_CR29) 2011; 57 B Pfleiderer (BFnpp201361_CR37) 2002; 17 DP Auer (BFnpp201361_CR2) 2000; 47 MT Rogan (BFnpp201361_CR43) 1997; 390 J Shlik (BFnpp201361_CR51) 1997; 22 JH Krystal (BFnpp201361_CR27) 2010; 24 C Riaza Bermudo-Soriano (BFnpp201361_CR42) 2011; 100 Y Mashhoon (BFnpp201361_CR32) 2011; 35 MM Blanchard (BFnpp201361_CR6) 2009; 33 R Rupprecht (BFnpp201361_CR46) 2009; 325 AL Malizia (BFnpp201361_CR30) 1998; 55 A Strohle (BFnpp201361_CR53) 2002; 159 P Zwanzger (BFnpp201361_CR59) 2005; 30 KS White (BFnpp201361_CR56) 2002 DV Sheehan (BFnpp201361_CR50) 1997; 12 RC Kessler (BFnpp201361_CR25) 1998; 55 EI Martin (BFnpp201361_CR31) 2010; 30 SJ Mathew (BFnpp201361_CR33) 2005; 162 A Strohle (BFnpp201361_CR52) 2003; 60 DW Brann (BFnpp201361_CR9) 1997; 18 V Bergink (BFnpp201361_CR4) 2004; 14 D Eser (BFnpp201361_CR13) 2005; 30 G Hasler (BFnpp201361_CR20) 2010; 167 C Pittenger (BFnpp201361_CR39) 2008; 22 KJ Ressler (BFnpp201361_CR41) 2004; 61 PD Arnold (BFnpp201361_CR1) 2009; 172 TV Bliss (BFnpp201361_CR7) 1993; 361 PP Roy-Byrne (BFnpp201361_CR44) 2000; 176 K Domschke (BFnpp201361_CR12) 2008; 14 JM Stutzmann (BFnpp201361_CR54) 1989; 99 ID Grachev (BFnpp201361_CR18) 2000; 5 AW Goddard (BFnpp201361_CR16) 2001; 58 TE Salt (BFnpp201361_CR47) 1996; 48 G Sanacora (BFnpp201361_CR48) 1999; 56 DL Walker (BFnpp201361_CR55) 2002; 71 GB Kaplan (BFnpp201361_CR23) 2011; 99 JP Herman (BFnpp201361_CR21) 2000; 422 KL Phan (BFnpp201361_CR38) 2005; 16 RM Berman (BFnpp201361_CR5) 2000; 47 M Hoerst (BFnpp201361_CR22) 2010; 67 D Koszycki (BFnpp201361_CR26) 1998; 8 B Pfleiderer (BFnpp201361_CR36) 2003; 122 DJ Dillon (BFnpp201361_CR11) 1987; 20 SW Provencher (BFnpp201361_CR40) 1993; 30 T Schunck (BFnpp201361_CR49) 2006; 31 P Zwanzger (BFnpp201361_CR57) 2012; 29 9331548 - Endocr Rev. 1997 Oct;18(5):678-700 15520361 - Arch Gen Psychiatry. 2004 Nov;61(11):1136-44 12694892 - Psychiatry Res. 2003 Apr 1;122(3):185-92 21569789 - Pharmacol Biochem Behav. 2012 Feb;100(4):752-74 9707382 - Arch Gen Psychiatry. 1998 Aug;55(8):715-20 24939759 - Neuropsychopharmacology. 2014 Oct;39(11):2706 11386984 - Arch Gen Psychiatry. 2001 Jun;58(6):556-61 12498744 - Neuroimage. 2002 Dec;17(4):1705-10 20603446 - Arch Gen Psychiatry. 2010 Sep;67(9):946-54 11032381 - Mol Psychiatry. 2000 Sep;5(5):482-8 9401314 - J Psychiatry Neurosci. 1997 Nov;22(5):332-40 3575564 - Psychiatry Res. 1987 Feb;20(2):97-105 20832657 - Clin Lab Med. 2010 Dec;30(4):865-91 8830348 - Prog Neurobiol. 1996 Jan;48(1):55-72 15944741 - J Psychiatry Neurosci. 2005 May;30(3):167-75 8296900 - Am J Psychiatry. 1994 Feb;151(2):261-3 16330605 - Am J Psychiatry. 2005 Dec;162(12):2379-81 15056476 - Eur Neuropsychopharmacol. 2004 May;14(3):175-83 10565505 - Arch Gen Psychiatry. 1999 Nov;56(11):1043-7 2574482 - Psychopharmacology (Berl). 1989;99(4):515-9 9403688 - Nature. 1997 Dec 11;390(6660):604-7 10739407 - Am J Psychiatry. 2000 Apr;157(4):493-505 18838633 - Arch Gen Psychiatry. 2008 Oct;65(10):1166-75 22923187 - Eur Arch Psychiatry Clin Neurosci. 2012 Nov;262 Suppl 2:S107-12 22553078 - Depress Anxiety. 2012 Sep;29(9):762-74 10861512 - J Comp Neurol. 2000 Jul 3;422(3):352-62 23059050 - Biol Psychiatry. 2013 Feb 15;73(4):337-44 21616118 - Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1709-13 12578433 - Arch Gen Psychiatry. 2003 Feb;60(2):161-8 15467707 - Neuropsychopharmacology. 2005 Jan;30(1):192-5 20634372 - Am J Psychiatry. 2010 Oct;167(10):1226-31 10755069 - Br J Psychiatry. 2000 Mar;176:229-35 11772707 - Am J Psychiatry. 2002 Jan;159(1):145-7 9736006 - Arch Gen Psychiatry. 1998 Sep;55(9):801-8 21256147 - Pharmacol Biochem Behav. 2011 Aug;99(2):217-28 15671874 - Neuroreport. 2005 Feb 8;16(2):183-6 21640838 - Neuroimage. 2011 Aug 15;57(4):1324-30 19811776 - Biol Psychiatry. 2010 Feb 15;67(4):365-70 10686270 - Biol Psychiatry. 2000 Feb 15;47(4):351-4 16600640 - Neuroimage. 2006 Jul 1;31(3):1197-208 10686265 - Biol Psychiatry. 2000 Feb 15;47(4):305-13 17123835 - Neuroimage. 2007 Jan 15;34(2):671-8 8139448 - Magn Reson Med. 1993 Dec;30(6):672-9 9750972 - Depress Anxiety. 1998;8(1):1-7 19324536 - Psychiatry Res. 2009 May 15;172(2):136-9 19497336 - Neurosci Biobehav Rev. 2009 Jul;33(7):1145-54 19075727 - Curr Pharm Des. 2008;14(33):3508-17 3282478 - Arch Gen Psychiatry. 1988 May;45(5):413-22 12700707 - Neuropsychopharmacology. 2003 May;28(5):979-84 8421494 - Nature. 1993 Jan 7;361(6407):31-9 24939760 - Neuropsychopharmacology. 2014 Oct;39(11):2707-8 21119734 - Nat Rev Drug Discov. 2010 Dec;9(12):971-88 11830172 - Pharmacol Biochem Behav. 2002 Mar;71(3):379-92 10664826 - Biol Psychiatry. 2000 Jan 15;47(2):107-11 18698875 - CNS Drugs. 2008;22(9):761-86 18095276 - Hum Brain Mapp. 2009 Feb;30(2):511-22 20658799 - CNS Drugs. 2010 Aug;24(8):669-93 19541954 - Science. 2009 Jul 24;325(5939):490-3 |
References_xml | – volume: 14 start-page: 3508 year: 2008 ident: BFnpp201361_CR12 publication-title: Curr Pharm Des doi: 10.2174/138161208786848784 – volume: 47 start-page: 305 year: 2000 ident: BFnpp201361_CR2 publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(99)00159-6 – volume: 100 start-page: 752 year: 2011 ident: BFnpp201361_CR42 publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2011.04.010 – volume: 47 start-page: 107 year: 2000 ident: BFnpp201361_CR24 publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(99)00118-3 – volume: 48 start-page: 55 year: 1996 ident: BFnpp201361_CR47 publication-title: Prog Neurobiol doi: 10.1016/0301-0082(95)00047-X – volume: 47 start-page: 351 year: 2000 ident: BFnpp201361_CR5 publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(99)00230-9 – volume: 17 start-page: 1705 year: 2002 ident: BFnpp201361_CR37 publication-title: Neuroimage doi: 10.1006/nimg.2002.1308 – start-page: 47 volume-title: Cortex Cerebri year: 1983 ident: BFnpp201361_CR10 doi: 10.1007/978-3-642-68962-8 – volume: 55 start-page: 715 year: 1998 ident: BFnpp201361_CR30 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.55.8.715 – volume: 122 start-page: 185 year: 2003 ident: BFnpp201361_CR36 publication-title: Psychiatr Res Neuroimaging doi: 10.1016/S0925-4927(03)00003-9 – start-page: 328 volume-title: Anxiety and its Disorders year: 2002 ident: BFnpp201361_CR56 – volume: 31 start-page: 1197 year: 2006 ident: BFnpp201361_CR49 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2006.01.035 – volume: 9 start-page: 971 year: 2010 ident: BFnpp201361_CR45 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3295 – volume: 8 start-page: 1 year: 1998 ident: BFnpp201361_CR26 publication-title: Depress Anxiety doi: 10.1002/(SICI)1520-6394(1998)8:1<1::AID-DA1>3.0.CO;2-G – volume: 159 start-page: 145 year: 2002 ident: BFnpp201361_CR53 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.159.1.145 – volume: 34 start-page: 671 year: 2007 ident: BFnpp201361_CR15 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2006.10.004 – volume: 20 start-page: 97 year: 1987 ident: BFnpp201361_CR11 publication-title: Psychiatry Res doi: 10.1016/0165-1781(87)90002-3 – volume: 30 start-page: 672 year: 1993 ident: BFnpp201361_CR40 publication-title: Magn Reson Med doi: 10.1002/mrm.1910300604 – volume: 16 start-page: 183 year: 2005 ident: BFnpp201361_CR38 publication-title: Neuroreport doi: 10.1097/00001756-200502080-00024 – volume: 12 start-page: 232 year: 1997 ident: BFnpp201361_CR50 publication-title: Eur Psychiatry doi: 10.1016/S0924-9338(97)83297-X – volume: 151 start-page: 261 year: 1994 ident: BFnpp201361_CR8 publication-title: Am J Psychiatry doi: 10.1176/ajp.151.2.261 – volume: 262 start-page: 107 issue: Suppl 2 year: 2012 ident: BFnpp201361_CR34 publication-title: Eur Arch Psychiatry Clin Neurosci doi: 10.1007/s00406-012-0352-5 – volume: 30 start-page: 192 year: 2005 ident: BFnpp201361_CR13 publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300572 – volume: 390 start-page: 604 year: 1997 ident: BFnpp201361_CR43 publication-title: Nature doi: 10.1038/37601 – volume: 60 start-page: 161 year: 2003 ident: BFnpp201361_CR52 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.60.2.161 – volume: 172 start-page: 136 year: 2009 ident: BFnpp201361_CR1 publication-title: Psychiatry Res doi: 10.1016/j.pscychresns.2009.02.005 – volume: 30 start-page: 167 year: 2005 ident: BFnpp201361_CR59 publication-title: J Psychiatry Neurosci – volume: 18 start-page: 678 year: 1997 ident: BFnpp201361_CR9 publication-title: Endocr Rev – volume: 35 start-page: 1709 year: 2011 ident: BFnpp201361_CR32 publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/j.pnpbp.2011.05.006 – volume: 361 start-page: 31 year: 1993 ident: BFnpp201361_CR7 publication-title: Nature doi: 10.1038/361031a0 – volume: 22 start-page: 761 year: 2008 ident: BFnpp201361_CR39 publication-title: CNS Drugs doi: 10.2165/00023210-200822090-00004 – volume: 58 start-page: 556 year: 2001 ident: BFnpp201361_CR16 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.58.6.556 – volume: 67 start-page: 946 year: 2010 ident: BFnpp201361_CR22 publication-title: Arch Gen Psychiatry doi: 10.1001/archgenpsychiatry.2010.93 – volume: 99 start-page: 217 year: 2011 ident: BFnpp201361_CR23 publication-title: Pharmacol Biochem Behav doi: 10.1016/j.pbb.2011.01.009 – volume: 65 start-page: 1166 year: 2008 ident: BFnpp201361_CR19 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.65.10.1166 – volume: 30 start-page: 865 year: 2010 ident: BFnpp201361_CR31 publication-title: Clin Lab Med doi: 10.1016/j.cll.2010.07.006 – volume: 73 start-page: 337 year: 2013 ident: BFnpp201361_CR28 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2012.09.004 – volume: 22 start-page: 332 year: 1997 ident: BFnpp201361_CR51 publication-title: J Psychiatry Neurosci – volume: 325 start-page: 490 year: 2009 ident: BFnpp201361_CR46 publication-title: Science doi: 10.1126/science.1175055 – volume: 67 start-page: 365 year: 2010 ident: BFnpp201361_CR35 publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2009.07.036 – volume: 71 start-page: 379 year: 2002 ident: BFnpp201361_CR55 publication-title: Pharmacol Biochem Behav doi: 10.1016/S0091-3057(01)00698-0 – volume: 167 start-page: 1226 year: 2010 ident: BFnpp201361_CR20 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.2010.09070994 – volume: 422 start-page: 352 year: 2000 ident: BFnpp201361_CR21 publication-title: J Comp Neurol doi: 10.1002/1096-9861(20000703)422:3<352::AID-CNE3>3.0.CO;2-F – volume: 176 start-page: 229 year: 2000 ident: BFnpp201361_CR44 publication-title: Br J Psychiatry doi: 10.1192/bjp.176.3.229 – volume: 24 start-page: 669 year: 2010 ident: BFnpp201361_CR27 publication-title: CNS Drugs doi: 10.2165/11533230-000000000-00000 – volume: 30 start-page: 511 year: 2009 ident: BFnpp201361_CR14 publication-title: Hum Brain Mapp doi: 10.1002/hbm.20522 – volume: 157 start-page: 493 year: 2000 ident: BFnpp201361_CR17 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.157.4.493 – volume: 99 start-page: 515 year: 1989 ident: BFnpp201361_CR54 publication-title: Psychopharmacology (Berl) doi: 10.1007/BF00589901 – volume: 55 start-page: 801 year: 1998 ident: BFnpp201361_CR25 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.55.9.801 – volume: 61 start-page: 1136 year: 2004 ident: BFnpp201361_CR41 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.61.11.1136 – volume: 29 start-page: 762 year: 2012 ident: BFnpp201361_CR57 publication-title: Depress Anxiety doi: 10.1002/da.21919 – volume: 28 start-page: 979 year: 2003 ident: BFnpp201361_CR58 publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300131 – volume: 56 start-page: 1043 year: 1999 ident: BFnpp201361_CR48 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.56.11.1043 – volume: 14 start-page: 175 year: 2004 ident: BFnpp201361_CR4 publication-title: Eur Neuropsychopharmacol doi: 10.1016/S0924-977X(03)00100-7 – volume: 162 start-page: 2379 year: 2005 ident: BFnpp201361_CR33 publication-title: Am J Psychiatry doi: 10.1176/appi.ajp.162.12.2379 – volume: 45 start-page: 413 year: 1988 ident: BFnpp201361_CR3 publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.1988.01800290027004 – volume: 33 start-page: 1145 year: 2009 ident: BFnpp201361_CR6 publication-title: Neurosci Biobehav Rev doi: 10.1016/j.neubiorev.2009.05.009 – volume: 5 start-page: 482 year: 2000 ident: BFnpp201361_CR18 publication-title: Mol Psychiatry doi: 10.1038/sj.mp.4000778 – volume: 57 start-page: 1324 year: 2011 ident: BFnpp201361_CR29 publication-title: Neuroimage doi: 10.1016/j.neuroimage.2011.05.048 – reference: 9401314 - J Psychiatry Neurosci. 1997 Nov;22(5):332-40 – reference: 21640838 - Neuroimage. 2011 Aug 15;57(4):1324-30 – reference: 15671874 - Neuroreport. 2005 Feb 8;16(2):183-6 – reference: 8421494 - Nature. 1993 Jan 7;361(6407):31-9 – reference: 12578433 - Arch Gen Psychiatry. 2003 Feb;60(2):161-8 – reference: 16600640 - Neuroimage. 2006 Jul 1;31(3):1197-208 – reference: 18095276 - Hum Brain Mapp. 2009 Feb;30(2):511-22 – reference: 8139448 - Magn Reson Med. 1993 Dec;30(6):672-9 – reference: 9736006 - Arch Gen Psychiatry. 1998 Sep;55(9):801-8 – reference: 21256147 - Pharmacol Biochem Behav. 2011 Aug;99(2):217-28 – reference: 19324536 - Psychiatry Res. 2009 May 15;172(2):136-9 – reference: 18698875 - CNS Drugs. 2008;22(9):761-86 – reference: 15056476 - Eur Neuropsychopharmacol. 2004 May;14(3):175-83 – reference: 11830172 - Pharmacol Biochem Behav. 2002 Mar;71(3):379-92 – reference: 8296900 - Am J Psychiatry. 1994 Feb;151(2):261-3 – reference: 10664826 - Biol Psychiatry. 2000 Jan 15;47(2):107-11 – reference: 11032381 - Mol Psychiatry. 2000 Sep;5(5):482-8 – reference: 3282478 - Arch Gen Psychiatry. 1988 May;45(5):413-22 – reference: 9707382 - Arch Gen Psychiatry. 1998 Aug;55(8):715-20 – reference: 19497336 - Neurosci Biobehav Rev. 2009 Jul;33(7):1145-54 – reference: 19811776 - Biol Psychiatry. 2010 Feb 15;67(4):365-70 – reference: 15520361 - Arch Gen Psychiatry. 2004 Nov;61(11):1136-44 – reference: 11386984 - Arch Gen Psychiatry. 2001 Jun;58(6):556-61 – reference: 9331548 - Endocr Rev. 1997 Oct;18(5):678-700 – reference: 19541954 - Science. 2009 Jul 24;325(5939):490-3 – reference: 15467707 - Neuropsychopharmacology. 2005 Jan;30(1):192-5 – reference: 10565505 - Arch Gen Psychiatry. 1999 Nov;56(11):1043-7 – reference: 18838633 - Arch Gen Psychiatry. 2008 Oct;65(10):1166-75 – reference: 8830348 - Prog Neurobiol. 1996 Jan;48(1):55-72 – reference: 23059050 - Biol Psychiatry. 2013 Feb 15;73(4):337-44 – reference: 12694892 - Psychiatry Res. 2003 Apr 1;122(3):185-92 – reference: 17123835 - Neuroimage. 2007 Jan 15;34(2):671-8 – reference: 24939760 - Neuropsychopharmacology. 2014 Oct;39(11):2707-8 – reference: 11772707 - Am J Psychiatry. 2002 Jan;159(1):145-7 – reference: 10755069 - Br J Psychiatry. 2000 Mar;176:229-35 – reference: 24939759 - Neuropsychopharmacology. 2014 Oct;39(11):2706 – reference: 22923187 - Eur Arch Psychiatry Clin Neurosci. 2012 Nov;262 Suppl 2:S107-12 – reference: 3575564 - Psychiatry Res. 1987 Feb;20(2):97-105 – reference: 10686265 - Biol Psychiatry. 2000 Feb 15;47(4):305-13 – reference: 2574482 - Psychopharmacology (Berl). 1989;99(4):515-9 – reference: 12498744 - Neuroimage. 2002 Dec;17(4):1705-10 – reference: 22553078 - Depress Anxiety. 2012 Sep;29(9):762-74 – reference: 20603446 - Arch Gen Psychiatry. 2010 Sep;67(9):946-54 – reference: 21616118 - Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1709-13 – reference: 10861512 - J Comp Neurol. 2000 Jul 3;422(3):352-62 – reference: 10739407 - Am J Psychiatry. 2000 Apr;157(4):493-505 – reference: 16330605 - Am J Psychiatry. 2005 Dec;162(12):2379-81 – reference: 20634372 - Am J Psychiatry. 2010 Oct;167(10):1226-31 – reference: 10686270 - Biol Psychiatry. 2000 Feb 15;47(4):351-4 – reference: 12700707 - Neuropsychopharmacology. 2003 May;28(5):979-84 – reference: 21119734 - Nat Rev Drug Discov. 2010 Dec;9(12):971-88 – reference: 9403688 - Nature. 1997 Dec 11;390(6660):604-7 – reference: 9750972 - Depress Anxiety. 1998;8(1):1-7 – reference: 19075727 - Curr Pharm Des. 2008;14(33):3508-17 – reference: 20832657 - Clin Lab Med. 2010 Dec;30(4):865-91 – reference: 20658799 - CNS Drugs. 2010 Aug;24(8):669-93 – reference: 21569789 - Pharmacol Biochem Behav. 2012 Feb;100(4):752-74 – reference: 15944741 - J Psychiatry Neurosci. 2005 May;30(3):167-75 |
SSID | ssj0015768 |
Score | 2.2406497 |
Snippet | According to preclinical studies, glutamate has been implicated in the pathogenesis of anxiety. In order to elucidate the role of glutamate in anxiety and... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1648 |
SubjectTerms | Adrenocorticotropic Hormone - blood Adult Adult and adolescent clinical studies Anxiety disorders Anxiety disorders. Neuroses Benzodiazepines Biological and medical sciences Brain research Creatine - metabolism Functional Neuroimaging Glutamic Acid - metabolism Glutamine - metabolism Gyrus Cinguli - metabolism Heart Rate Hormones Humans Hydrocortisone - blood Hypothalamo-Hypophyseal System - metabolism Male Medical sciences Neurobiology Original Panic attacks Panic disorder Panic Disorder - blood Panic Disorder - chemically induced Panic Disorder - metabolism Pathogenesis Pituitary-Adrenal System - metabolism Psychiatric Status Rating Scales Psychiatry Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychotherapy Signal transduction Spectrum analysis Tetragastrin |
Title | Acute Shift in Glutamate Concentrations Following Experimentally Induced Panic with Cholecystokinin Tetrapeptide—A 3T-MRS Study in Healthy Subjects |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23463151 https://www.proquest.com/docview/1400189301 https://www.proquest.com/docview/1400624840 https://www.proquest.com/docview/1419366591 https://pubmed.ncbi.nlm.nih.gov/PMC3717541 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZbC2NQxpbu4q0LGpQ-jGq1LUu2n0YWkpVBSmhTyJuxZJmGdU46Owz_j_3gnSM7TjNKX_yik1hYR9J3rh8hxyE3Oshzw0wufBZk8Eh9lbM8EHAhYmRNYYHz5EKeXwc_5mLeOtzKNq1ycybagzpbavSRn4Eh4Hpwubre19UdQ9YojK62FBpPyT62LsOUrnDeGVweYmmLImPOwBabt_V5Lo_OihU2q_T4F-nt3EgHq7SEj5M3rBYPwc7_syfvXUfjl-RFiyPpoFn4V-SJKXrkcFCADf2rpifUZnZal3mPPJu0AfQeOZk2rarrUzrbVl6Vp_YXXRPr-pD8Heh1ZejVzSKv6KKg30FDU0C3hg6x0LFou-2WdAyKtPwDFyAd3SMLuK0pkoJok9FpWiw0RX8vHVoy3hrw5k_kpaAzU-EU4NTKDGMDymdscnlFMbexxpc2NVI1hdMN3UXla3I9Hs2G56xlcGAakFXFQjeUKuBKqDDLvUy5ufGMK-PMVZ6KUxeDenHmpzAQhLEUWcQVVxoGuW8iLfgbslcsC_OOUIVITYNBZ1KB0doUkJ5IXaF45Gc6Dx3yebOKiW7bmyPLxm1iw-w8SmDJE1zyRHoOOe6EV01Xj4fF-jvq0Mn6obS66JCjjX4k7d4vk62mOuRTNwy7FkMxaWGW60ZG-gFY14_JALiWUsTwP28bldtOgAeSA1hzSLijjJ0Adg3fHSkWN7Z7OAcDXgTe-8en_oE89y3xB6Y6HpG96vfafAT4Vam-3WN9sv9tdDG9_AfAczRg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEB5VrQRICEHKT6CURSo9oC61vf6JDwiFkJDSJoraVMrNeNdrNaI4ATuq_B48B8_IjO04Dap66yWXnSQrzezMNzs78wHseUIrO44117FjcTvCj9CSMY9tBwMiVdYkNTgPhm7_3P42cSYb8HfZC0PPKpc-sXDU0UzRHfkhJgKGicHVMD_Nf3FijaLq6pJCozSLY51fYcqWfjz6gvp9Z1m97rjT5xWrAFcY7TPuYeYubSEd6UWxGUkj1qY2XD8ypCn90KBCkx9ZIS7Ynu86UUtIIRUuCku3FLFEoMvfsgWmMpuw9bk7HJ3WdQtC7wVu9QXH7G9SdQQaonWYzGk8pik-uOZaDHw4D1NUR1zyaNwEdP9_r3ktAPYew6MKubJ2aWpPYEMnDdhuJ5i1_8zZPivekhaX9A24N6hK9g3YH5XDsfMDNl71eqUHxTfqsdn5Nvxpq0Wm2dnFNM7YNGFf8UyEiKc161BrZVLN901ZD013doUhl3Wv0RNc5oxoSJSO2ChMporRDTPrFPS_OSLcH8SEwcY6oy2gn4w0520mxnxwesboNWVOf1p2ZeUM_SldUKVP4fxOtPsMNpNZol8Ak4QNFaaQOnSoPhwitnRCw5GiZUUq9prwfqnFQFUD1YnX4zIoCvuiFaDKA1J54JpN2KuF5-UckZvFdtfMoZa1PLew_ibsLO0jqLxNGqzORhPe1svoJ6j4EyZ6tihlXMvGfP42GYTzruv4-DvPS5NbbUDYrkB42ARvzRhrAZpTvr6STC-KeeXCQ4xqmy9v3_obuN8fD06Ck6Ph8St4YBW0I_TQcgc2s98L_RrBXyZ3qxPH4PtdH_J_ZKdxUQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLamIU1ICEHHpTCGkcYe0LzGcS7NA0JVt7IxOlWsk_oWYsfWKkZaSKop_4Nfw6_jHCfNVjTtbS998Wlr6dy-43MjZCcUWnnGaKaN7zIvhY_ElYYZzweHiJk1iQ3Ow9Pg6Nz7MvEna-TvshcGyyqXNtEa6nSm8I28A4GAw8G5Orxj6rKI0cHg0_wXww1SmGldrtOoROREl1cQvuUfjw-A1-9dd3A47h-xesMAU-D5CxZCFC89IX0Zpoan0jGaayeIUkdyGSUOJp2i1E3gwAujwE-7Qgqp4FC4uqtwYwSY_weh8DnqWDhpgj2OON4i2EgwiAMndW-gI7qdbI6DMrnYD_iKN3w0T3JgjKk2atwGef-v3LzhCgdPyOMaw9JeJXRPyZrOWmSzl0H8_rOku9RWldrn-hbZGNbJ-xbZHVVjsss9Or7u-sr37DeaAdrlJvnTU4tC07OLqSnoNKOfQTsSQNaa9rHJMqsn_eZ0AEI8uwLnSw9vLCq4LCkuJFE6paMkmyqKb820bxcBl4B1f-BODDrWBV4BLGaqGetRMWbDb2cU6ypL_NOqP6ukYFnxqSp_Rs7vhbfPyXo2y_RLQiWiRAXBpE58zBQngDL9xPGl6LqpMmGbfFhyMVb1aHXc8HEZ2xS_6MbA8hhZHge8TXYa4nk1UeR2su0VcWho3TCwetAmW0v5iGu7k8fXWtIm75pjsBiYBkoyPVtUNIHrQWR_Fw0A-yDwI_idF5XIXV9AeIEAoNgm4YowNgQ4sXz1JJte2MnlIgS06vFXd1_9LdkA1Y6_Hp-evCYPXbt_BCsut8h68Xuh3wAKLOS2VTdKvt-3fv8DNqR0IQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acute+Shift+in+Glutamate+Concentrations+Following+Experimentally+Induced+Panic+with+Cholecystokinin+Tetrapeptide-A+3T-MRS+Study+in+Healthy+Subjects&rft.jtitle=Neuropsychopharmacology+%28New+York%2C+N.Y.%29&rft.au=Zwanzger%2C+Peter&rft.au=Zavorotnyy%2C+Maxim&rft.au=Gencheva%2C+Elena&rft.au=Diemer%2C+Julia&rft.date=2013-08-01&rft.issn=0893-133X&rft.volume=38&rft.issue=9&rft.spage=1648&rft.epage=1654&rft_id=info:doi/10.1038%2Fnpp.2013.61&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-133X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-133X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-133X&client=summon |